Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio
Business Exposures
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
What is CE Certification for High Quality Pharmaceutical Machine Manufacturers?
Via AB Newswire
Topics Product Recall
Exposures Legal Product Safety
News headline image
Revolution Medicines (RVMD): The New Titan of the RAS Pathway (2026 Research Feature)
Via Finterra
Topics Initial Public Offering
Tickers FIS GS JPM LLY RVMD
Exposures Product Safety Securities Market
BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Launches Proposed Public Offering to Support Commercialization and AI Initiatives
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
Tickers BEAT
Exposures Artificial Intelligence Intellectual Property Product Safety
News headline image
Why Is Praxis Precision Stock Soaring Tuesday? ↗
Via Benzinga
Exposures Product Safety
News headline image
FDA Warns Of Injury Risk Linked To Merit Medical Dialysis Kits ↗
Via Benzinga
Exposures Product Safety
Vivtone Unveils Xpure C Bluetooth Hearing Aids for Tailored and Effortless Hearing Experiences
Via AB Newswire
Exposures Product Safety
News headline image
MedTech Surge and Oncology Resilience Drive Johnson & Johnson to Q1 Earnings Beat
Via MarketMinute
Topics Bankruptcy Earnings Economy
Tickers AMGN ARM BSX ISRG JNJ KVUE
Exposures Financial Intellectual Property Interest Rates
News headline image
Johnson & Johnson Shatters Expectations in Q1 2026, Raising Full-Year Outlook as Healthcare Giant Pushes Toward $100 Billion Milestone
Via MarketMinute
Topics Economy Intellectual Property
Tickers AMGN BSX ISRG JNJ KVUE MDT
Exposures Economy Intellectual Property Product Safety
News headline image
Why Praxis, A Top 1% Biotech, Just Surged Into A Bullish Breakout ↗
Via Investor's Business Daily
Exposures Product Safety
News headline image
FDA Approval For Travere's Drug Expands Reach To Broader Rare Kidney Disease Patients ↗
Via Benzinga
Exposures Product Safety
News headline image
The RAS Revolution: A Deep Dive into Revolution Medicines’ Path to Dominance (2026 Report)
Via Finterra
Topics Economy Initial Public Offering Intellectual Property
Tickers ABBV AMGN BLK BMY LLY MRK
Exposures Intellectual Property Interest Rates Product Safety
News headline image
The New J&J: A 2026 Deep Dive into the Global Healthcare Titan
Via Finterra
Topics Artificial Intelligence Death Economy
Tickers BLK C JNJ KVUE MDT MS
Exposures Artificial Intelligence COVID-19 Death
News headline image
Travere Therapeutics Stock Skyrockets On FDA Approval ↗
Via Investor's Business Daily
Exposures Product Safety
News headline image
Earnings Preview: What to Expect From Regeneron Pharmaceuticals' Report
Via Barchart.com
Topics ETFs
Exposures Product Safety
News headline image
Pureluxtech Expands FDA-Cleared Red Light Therapy Portfolio for Global Wellness Brands OEM/ODM Manufacturer
Via Get News
Exposures Product Safety
News headline image
Cora Health Expands Telehealth Access to GLP-1 Medications Across 44 States
Via AB Newswire
Exposures Product Safety
News headline image
$30 Billion Per Year US Heart Failure Market Presents Huge Opportunity for Promising Drugs Advancing with Positive Trial Results for Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL)
Via Get News
Topics Intellectual Property
Tickers CRDL LLY TSX:CRDL
Exposures Intellectual Property Product Safety
News headline image
Revolution Medicines Soars on Phase 3 Trial Results. Is It Too Late to Buy?
Via Barchart.com
Exposures Product Safety
Why FDA Warehouse Inspections Catch More Businesses Off Guard Than They Should
Via BusinesNews Wire
Exposures Product Safety
News headline image
FDA Rejection Sparks Questions On Replimune Drug Approval Path ↗
Via Benzinga
Exposures Product Safety
News headline image
Ocular's Axpaxli Cuts Risk Of Worsening In Late-Stage AMD Study ↗
Via Benzinga
Tickers AMD
Exposures Product Safety
News headline image
Diclosan: The Modern Standard for Safe & Effective Disinfection
Via AB Newswire
Exposures Product Safety
News headline image
Organogenesis Clears Major FDA Hurdle: Path to First Non-Surgical Biologic for Knee Osteoarthritis Widens
Via MarketMinute
Tickers ANIK ORGO PCRX SYK ZBH
Exposures Product Safety
News headline image
Ascendis Pharma Completes Strategic Trifecta with U.S. Launch of YUVIWEL and Seven-Year Orphan Exclusivity
Via MarketMinute
Topics Economy
Tickers ASND AZN BBIO BMRN
Exposures Interest Rates Product Safety
News headline image
Amgen’s Subcutaneous TEPEZZA Data Sets New Gold Standard for Thyroid Eye Disease Treatment
Via MarketMinute
Tickers AMGN IMVT VRDN
Exposures Product Safety
News headline image
Kaplan Fox Reminds ImmunityBio, Inc. (NASDAQ: IBRX) Investors of a Securities Class Action Deadline on May 26, 2026
Via TheNewswire.com
Topics Lawsuit
Tickers IBRX
Exposures Financial Legal Product Safety
News headline image
Kaplan Fox Reminds ImmunityBio, Inc. (NASDAQ: IBRX) Investors of a Securities Class Action Deadline on May 26, 2026
Via NewMediaWire
Topics Lawsuit
Tickers IBRX
Exposures Financial Legal Product Safety
News headline image
The Radiopharmaceutical Renaissance: A Deep Dive into Telix Pharmaceuticals (TLX)
Via Finterra
Topics Economy Initial Public Offering
Tickers ASX:TLX ASX:XJO FIS JPM LLY NVS
Exposures Product Safety Securities Market Supply Chain
News headline image
The Science of Scale: An In-Depth Look at Regeneron Pharmaceuticals (REGN) in 2026
Via Finterra
Topics Earnings Economy Intellectual Property
Tickers ABBV AMGN LLY MRK REGN RHHBY
Exposures Financial Intellectual Property Interest Rates
News headline image
CORT SHAREHOLDER ACTION ALERT: Kaplan Fox Alerts Investors of a Class Action Lawsuit Against Corcept Therapeutics, Inc. (NASDAQ: CORT) and Lead Plaintiff Deadline on April 21, 2026
Via TheNewswire.com
Topics Lawsuit
Tickers CORT
Exposures Financial Legal Product Safety
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.